The clinical benefit of ADC therapy with T-DXd for patients with HER2-low BC has been established through the DESTINY-Breast04 (DB-04) trial (NCT03734029) and further supported by the DAISY trial (NCT04132960) [50]. This evidence concerns the gene ERBB2 and breast cancer.